Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Table 1

Patient characteristics, prior therapy, disease status, and toxicity.

	FG #	Age/PS	Gleason; score	aATC dose level	Metastatic disease sites	Prior therapy	Disease status	OS in days	Grade 3 toxicity
1	00469	66/PS-2	7	20 billion	Bone, lymph nodes, lung, and liver	Hormones; docetaxel; + estramustine	Progressed during aATC infusions	67	None
2	00488	82/PS-2	9	20 billion	Bone	Hormones; mitoxantrone	Progressed during aATC infusions	143	None
3	00566	75/PS-1	8	20 billion	Bone	Hormones	Progressed during aATC infusions	699	Chills
4	00594	85/PS-1	8	20 billion	Lymph nodes, bone	Hormones	Progressed during aATC infusions	136	Chills
5	60163	76/PS-1	6	40 billion	Bone, lung	Hormones	PR	598	Chills
6	60202	80/PS-1	8	40 billion	Bone	Hormones	MR	294	Chills
7	91760	69/PS-1	6	80 billion	Bone, lung	Hormones	MR	550	Chills, Malaise

PS: performance status; PR: partial remission; MR: minor response; OS: overall survival. There were no grades for toxicities on the NCI-immunotherapy toxicity protocol.